Insulin oral - Emisphere Technologies

Drug Profile

Insulin oral - Emisphere Technologies

Alternative Names: Oral insulin

Latest Information Update: 23 Sep 2010

Price : $50

At a glance

  • Originator Emisphere Technologies
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Nov 2006 Additional clinical results from a phase II study in patients with type 2 diabetes have been added to the Diabetes therapeutic trials section
  • 02 Nov 2006 Final results from a phase II clinical trial in patients with type 2 diabetes have been added to the Diabetes therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top